Trials / Completed
CompletedNCT00545675
Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness
Multi-center, Double-blind, Randomized, Comparative Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify and Depakote in 24-week Treatment of Mania in Patients With Bipolar Disorder Remitted After 6-week Treatment With Abilify and Depakote
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 146 (estimated)
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate the difference between Abilify with Depakote vs. Placebo with Depakote in 24-week treatment in patients with remission status after Abilify with Depakote in the 6-week study of acute mania in patients with bipolar disorder
Detailed description
Further study details as provided by Korea OIAA
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abilify(aripiprazole) | Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder |
| DRUG | Depakote (divalproate) | Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2007-10-17
- Last updated
- 2010-08-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00545675. Inclusion in this directory is not an endorsement.